| # | Title | Journal | Year | Citations |
|---|
| 1 | Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Blood | 2007 | 1,056 |
| 2 | Estimated Projection of US Cancer Incidence and Death to 2040 | JAMA Network Open | 2021 | 566 |
| 3 | Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma | Clinical Cancer Research | 2014 | 493 |
| 4 | The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis | Nature Communications | 2014 | 427 |
| 5 | Guidelines of care for the management of primary cutaneous melanoma | Journal of the American Academy of Dermatology | 2011 | 417 |
| 6 | Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response | Science | 2021 | 369 |
| 7 | Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial | Lancet Oncology, The | 2015 | 325 |
| 8 | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma | Expert Opinion on Investigational Drugs | 2007 | 289 |
| 9 | Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes | Nature Genetics | 2015 | 276 |
| 10 | COVID-19: a case for inhibiting IL-17? | Nature Reviews Immunology | 2020 | 244 |
| 11 | Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial | Lancet Oncology, The | 2014 | 239 |
| 12 | Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma | British Journal of Haematology | 2018 | 219 |
| 13 | Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci | Nature Communications | 2015 | 213 |
| 14 | Diverse types of dermatologic toxicities from immune checkpoint blockade therapy | Journal of Cutaneous Pathology | 2017 | 186 |
| 15 | Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome | British Journal of Dermatology | 2008 | 167 |
| 16 | Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials | Journal of the American Academy of Dermatology | 2015 | 156 |
| 17 | Total Skin Electron Beam and Non-Myeloablative Allogeneic Hematopoietic Stem-Cell Transplantation in Advanced Mycosis Fungoides and Sézary Syndrome | Journal of Clinical Oncology | 2010 | 149 |
| 18 | Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience | Investigational New Drugs | 2018 | 149 |
| 19 | The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF | Cancer Research | 2014 | 148 |
| 20 | Histomorphologic Assessment and Interobserver Diagnostic Reproducibility of Atypical Spitzoid Melanocytic Neoplasms With Long-term Follow-up | American Journal of Surgical Pathology | 2014 | 142 |
| 21 | Use of immunohistochemistry in melanocytic lesions | Journal of Cutaneous Pathology | 2008 | 126 |
| 22 | Autoimmune dermatologic toxicities from immune checkpoint blockade with anti‐PD‐1 antibody therapy: a report on bullous skin eruptions | Journal of Cutaneous Pathology | 2016 | 126 |
| 23 | Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome | Clinical Cancer Research | 2015 | 125 |
| 24 | Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma | Blood | 2012 | 122 |
| 25 | Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results | Bone Marrow Transplantation | 2003 | 120 |
| 26 | Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients | | 2018 | 118 |
| 27 | Sebaceous carcinoma: evidence-based clinical practice guidelines | Lancet Oncology, The | 2019 | 116 |
| 28 | Chemotherapy-induced alopecia | Journal of the American Academy of Dermatology | 2012 | 103 |
| 29 | Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression | Cell Cycle | 2014 | 103 |
| 30 | CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma | Journal of Investigative Dermatology | 2006 | 96 |
| 31 | Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children | American Journal of Surgical Pathology | 2013 | 96 |
| 32 | Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients | Journal of the American Academy of Dermatology | 2016 | 96 |
| 33 | A pilot quality-of-life instrument for acne rosacea | Journal of the American Academy of Dermatology | 2007 | 93 |
| 34 | Clinical study of noninvasivein vivomelanoma and nonmelanoma skin cancers using multimodal spectral diagnosis | Journal of Biomedical Optics | 2014 | 92 |
| 35 | Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma | Journal of the American Academy of Dermatology | 2010 | 90 |
| 36 | Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome | Blood | 2003 | 89 |
| 37 | Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients | Clinical and Experimental Dermatology | 2009 | 89 |
| 38 | Cutaneous manifestations of Hodgkin's disease | International Journal of Dermatology | 2006 | 86 |
| 39 | A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders | Clinical Cancer Research | 2009 | 84 |
| 40 | Molecular cancer prevention: Current status and future directions | Ca-A Cancer Journal for Clinicians | 2015 | 83 |
| 41 | Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides | Journal of the American Academy of Dermatology | 2009 | 79 |
| 42 | Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression | Cell Reports | 2017 | 78 |
| 43 | Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators | OncoImmunology | 2017 | 78 |
| 44 | Graft-versus-host disease | Journal of the American Academy of Dermatology | 2012 | 76 |
| 45 | Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome | Blood | 2014 | 76 |
| 46 | IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy | Cancer Immunology Research | 2019 | 76 |
| 47 | Treatment of Cutaneous T Cell Lymphoma | American Journal of Clinical Dermatology | 2002 | 72 |
| 48 | Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: A case series of 34 patients | Journal of the American Academy of Dermatology | 2014 | 71 |
| 49 | Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool | Journal of Cutaneous Pathology | 2009 | 69 |
| 50 | Prevalence and severity of pruritus in cutaneous T cell lymphoma | International Journal of Dermatology | 2012 | 68 |
